文献速递肝病

抗生素联合或不联合利福昔明治疗肝硬化危重症患者急性肝性脑病:双盲随机对照(ARiE)试验

Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
PubMed 文献 · Am J Gastroenterol · 2023-11-09

在重症监护病房(ICU)的显性肝性脑病(HE)肝硬化患者中,抗生素联合利福昔明与单用抗生素相比,HE逆转率、逆转时间及院内死亡率均无显著差异。亚组分析显示,利福昔明可降低失代偿期肝硬化患者的院内死亡率,但在慢加急性肝衰竭患者中无此效应。

要点

  • 在ICU显性HE肝硬化患者中,利福昔明联合抗生素未改善HE逆转率或院内死亡率。
  • 利福昔明与较低院内死亡率相关仅见于失代偿期肝硬化亚组,慢加急性肝衰竭亚组无此关联。
  • 利福昔明未影响内毒素水平,院内感染发生率两组无显著差异。

核心结论

  • 在ICU接受抗生素治疗的显性HE肝硬化患者中,加用利福昔明并未改善HE逆转率、逆转时间或院内死亡率。
  • 利福昔明可能降低失代偿期肝硬化患者的院内死亡率,但在慢加急性肝衰竭患者中未见此效应,原因可能与院内感染减少有关。

研究设计与样本

  • 双盲随机对照试验,纳入ICU的显性HE肝硬化患者,随机分为单用抗生素组(ab组)和抗生素联合利福昔明组(ab+r组),每组92例。
  • 主要比较HE逆转(或降低2级)、HE逆转时间、院内死亡率、院内感染及内毒素水平变化,并对失代偿期肝硬化和慢加急性肝衰竭患者进行亚组分析。

主要发现

  • ab组44.6%(41/92;95%CI 32-70.5)和ab+r组46.7%(43/92;95%CI 33.8-63)达到主要目标,P=0.84。
  • 达到主要目标的时间在ab组为3.65±1.82天,ab+r组为4.11±2.01天,P=0.27。
  • 院内死亡率ab组为62%,ab+r组为50%,P=0.13。
  • 院内感染发生率ab组为7%,ab+r组为13%,P=0.21。
  • 内毒素水平未受利福昔明影响;在失代偿期肝硬化患者中,利福昔明与较低的院内死亡率相关(HR 0.39,95%CI 0.2-0.76),但在慢加急性肝衰竭患者中无此关联(HR 0.99,95%CI 0.6-1.63)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Critically ill patients with cirrhosis admitted to the intensive care unit (ICU) are usually on broad-spectrum antibiotics because of suspected infection or as a hospital protocol. It is unclear if additional rifaximin has any synergistic effect with broad-spectrum antibiotics in ICU patients with acute overt hepatic encephalopathy (HE). METHODS: In this double-blind trial, patients with overt HE admitted to ICU were randomized to receive antibiotics (ab) alone or antibiotics with rifaximin (ab + r). Resolution (or 2 grade reduction) of HE, time to resolution of HE, in-hospital mortality, nosocomial infection, and changes in endotoxin levels were compared between the 2 groups. A subgroup analysis of patients with decompensated cirrhosis and acute-on-chronic liver failure was performed. RESULTS: Baseline characteristics and severity scores were similar among both groups (92 in each group). Carbapenems and cephalosporin with beta-lactamase inhibitors were the most commonly used ab. On Kaplan-Meier analysis, 44.6% (41/92; 95% confidence interval [CI], 32-70.5) in ab-only arm and 46.7% (43/92; 95% CI, 33.8-63) in ab + r arm achieved the primary objective ( P = 0.84).Time to achieve the primary objective (3.65 ± 1.82 days and 4.11 ± 2.01 days; P = 0.27) and in-hospital mortality were similar among both groups (62% vs 50%; P = 0.13). Seven percent and 13% in the ab and ab + r groups developed nosocomial infections ( P = 0.21). Endotoxin levels were unaffected by rifaximin. Rifaximin led to lower in-hospital mortality (hazard ratio: 0.39 [95% CI, 0.2-0.76]) in patients with decompensated cirrhosis but not in patients with acute-on-chronic liver failure (hazard ratio: 0.99 [95% CI, 0.6-1.63]) because of reduced nosocomial infections. DISCUSSION: Reversal of overt HE in those on ab was comparable with those on ab + r.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kulkarni AV, Avadhanam M, Karandikar P, et al. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial. Am J Gastroenterol. 2023. PMID: 37942950. doi:10.14309/ajg.0000000000002575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。